Related Experiment Video
Updated: Jun 26, 2025

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Dihydroquercetin alleviates dopamine neuron loss via regulating TREM2 activation
Rong Yang1, Dai-di Li1, Xiao-Xian Li1
1Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province and Laboratory Animal Centre, Zunyi Medical University, Zunyi, Guizhou, China.
Background:
Parkinson's disease (PD) is a prevalent neurodegenerative disorder, marked by the degeneration of dopamine (DA) neurons in the substantia nigra (SN). Current evidence strongly suggests that neuroinflammation, primarily mediated by microglia, contributes to PD pathogenesis. Triggering receptor expressed on myeloid cells 2 (TREM2) might serve as a promising therapeutic target for PD due to its ability to suppress neuroinflammation. Dihydroquercetin (DHQ) is an important natural dihydroflavone and confers apparent anti-inflammatory, antioxidant and anti-fibrotic effects. Recently, DHQ-mediated neuroprotection was exhibited. However, the specific mechanisms of its neuroprotective effects remain incompletely elucidated.
Methods:
In this study, rat models were utilized to induce damage to DA neurons using lipopolysaccharide (LPS) and 6-hydroxydopamine (6-OHDA) to assess the impacts of DHQ on the loss of DA neurons. Furthermore, DA neuronal MN9D cells and microglial BV2 cells were employed to investigate the function of TREM2 in DHQ-mediated DA neuroprotection. Finally, TREM2 knockout mice were used to investigate whether the neuroprotective effects mediated by DHQ through a mechanism dependent on TREM2.
Results:
The main findings demonstrated that DHQ effectively protected DA neurons against neurotoxicity induced by LPS and 6-OHDA and inhibited microglia-elicited neuroinflammation. Meanwhile, DHQ promoted microglial TREM2 signaling activation. Notably, DHQ failed to reduce inflammatory cytokines release and further present neuroprotection from DA neurotoxicity upon TREM2 silencing. Similarly, DHQ didn't exert DA neuroprotection in TREM2 knockout mice.
Conclusions:
These findings suggest that DHQ exerted DA neuroprotection by regulating microglia TREM2 activation.
Insights
Dihydroquercetin (DHQ) protects dopamine neurons in Parkinson's disease by activating the TREM2 receptor on microglia, reducing neuroinflammation and neuronal loss. This mechanism is crucial for DHQ's neuroprotective effects.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Parkinson's disease (PD) involves dopamine neuron degeneration and neuroinflammation.
- Microglia-mediated neuroinflammation is a key factor in PD pathogenesis.
- Triggering receptor expressed on myeloid cells 2 (TREM2) is a potential therapeutic target for suppressing neuroinflammation in PD.
Purpose of the Study:
- To investigate the neuroprotective mechanisms of dihydroquercetin (DHQ) in Parkinson's disease.
- To determine if DHQ's neuroprotection is mediated by TREM2 signaling in microglia.
Main Methods:
- Utilized rat models with induced dopamine neuron damage (LPS, 6-OHDA) to test DHQ.
- Employed neuronal (MN9D) and microglial (BV2) cell lines to study TREM2 function.
- Used TREM2 knockout mice to confirm TREM2-dependent effects of DHQ.
Main Results:
- DHQ protected dopamine neurons and inhibited neuroinflammation induced by LPS and 6-OHDA.
- DHQ activated microglial TREM2 signaling.
- DHQ's neuroprotective effects and reduction of inflammatory cytokines were abolished upon TREM2 silencing or in TREM2 knockout mice.
Conclusions:
- DHQ exerts neuroprotection in Parkinson's disease models.
- DHQ's mechanism involves the regulation of microglial TREM2 activation.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drugs Affecting Neurotransmitter Synthesis
Parkinson's Disease: Overview
Neural Regulation
Alzheimer's Disease: Treatment
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

